Literature DB >> 263903

Pathologic aspects of juvenile chronic polyarthritis.

E G Bywaters.   

Abstract

The pathological changes in juvenile chronic polyarthritis are similar to those of adult chronic polyarthritis, although perhaps rather more variable, according to the severity and the phase of the disease. The differences that are seen depend on age, developmental stage, growth, and perhaps a greater regenerative capacity. The nodules of seronegative diseases resemble those of rheumatic fever and are not seen in adult onset seropositive rheumatoid arthritis. In addition, ankylosis of the cervical spine is a characteristic feature seen also in adult onset Still's disease.

Entities:  

Mesh:

Year:  1977        PMID: 263903

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  3 in total

1.  Novel self-epitopes derived from aggrecan, fibrillin, and matrix metalloproteinase-3 drive distinct autoreactive T-cell responses in juvenile idiopathic arthritis and in health.

Authors:  Sylvia Kamphuis; Kolbrún Hrafnkelsdóttir; Mark R Klein; Wilco de Jager; Margje H Haverkamp; Jolanda H M van Bilsen; Salvatore Albani; Wietse Kuis; Marca H M Wauben; Berent J Prakken
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

2.  Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells.

Authors:  Daniel S Pharoah; Hemlata Varsani; Richard W Tatham; Katy R Newton; Wilco de Jager; Berent J Prakken; Nigel Klein; Lucy R Wedderburn
Journal:  Arthritis Res Ther       Date:  2006-02-28       Impact factor: 5.156

3.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.